Insider Trading & Ownership of COLUMN GROUP II, LP

Location
San Francisco, CA
Summary
The estimated value of insider holdings of COLUMN GROUP II, LP is at least $63,535,487 dollars as of 23 Dec 2024. COLUMN GROUP II, LP is the Former 10% Owner of RAPT Therapeutics, Inc. and owns shares of RAPT Therapeutics, Inc. stock worth about $32.9M. COLUMN GROUP II, LP is the 10%+ Owner of Oric Pharmaceuticals, Inc. and owns shares of Oric Pharmaceuticals, Inc. (ORIC) stock worth about $30.64M.
Signature
/s/ James Evangelista, as Attorney-in-fact for The Column Group II GP LP
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow COLUMN GROUP II, LP and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • COLUMN GROUP II, LP has 2 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $63,535,487.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: RAPT Therapeutics, Inc. ($32,898,807).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of COLUMN GROUP II, LP

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
RAPT RAPT Therapeutics, Inc. Former 10% Owner $32,898,807 23 Dec 2024
ORIC Oric Pharmaceuticals, Inc. 10%+ Owner $30,636,680 12 Nov 2021

Insider Transactions Reported by COLUMN GROUP II, LP:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .